1 / 14

Ethical Stakes and Therapeutic Innovation

Ethical Stakes and Therapeutic Innovation. Yannick PLETAN, MD, MSc, FFPM Vice-President Pfizer, France Chief Medical Officer. A few statements. Novelty is not innovation There is no unique definition for innovation Innovation has no societal value per se

lali
Download Presentation

Ethical Stakes and Therapeutic Innovation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Ethical Stakes and Therapeutic Innovation Yannick PLETAN, MD, MSc, FFPM Vice-President Pfizer, France Chief Medical Officer

  2. A few statements • Novelty is not innovation • There is no unique definition for innovation • Innovation has no societal value per se • Until innovation is recognized as a progress, quest for innovation entails risks rather than benefits, and poses ethical issues • Human Research is the most codified activity in most countries • Newer ethical aspirations surface as we move forward • Seeking innovation imposes choices • Developers may have different perspectives that impact on choices • Context may change the value and outcome of such choices • Any choice in this matter has an ethical dimension or consequence French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  3. Innovation for some, not for others • The WHO 200-medicine list • Innovation through official awards (Gallien) • Innovation assessed by the Pharmaceutical Industry • An FDA view over Innovation • Evidence Based Medicine • Innovation as the price granted for the new medicines • Innovation, a desperate quest for Rare Diseases French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  4. A Few Illustrations • From innovation to progress • An example of a development dilemma • Value of innovation depending on posture: public health versus patients’ expectations • Value of innovation depending on context • Responsibility and innovation French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  5. Penicillin dicovery Innovation = Fleming, 1943 TECHNICAL PROGRESS = INDUSTRIAL FERMENTATION SCIENTIFIC PROGRESS Pfizer, 1944 MEDICAL PROGRESS Other antibiotics INDIVIDUALS Soldiers, 1944 Patients ECONOMICAL PROGRESS Increased working capacity Industrial development SOCIETAL PROGRESS Decrease of mortality (infectious, cardio-vascular, renal, cerebral) Improvement in duration and quality of life French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  6. Molecule presenting with an important effect On some mycobacteria Including tuberculosis agent = potential therapeutic value Potential options A B Tuberculosis treatment (millions of cases in the world) Developing countries Deprived populations Affordable daily treatment cost close to nil Mycobacterium Xenopi treatment, Nosocomial infections agent (hundreds of cases / world) Developped countries, ICUs, specialized wards No pre-established financial constraint Ideally = A + B = 2 distinct developments What if constraint upon resources ? French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  7. Impact of pathologies on quality of lifeThe Sickness Impact Profile: validation of a health status measure. Bergner M, et al. Med Care 1976. Lower QOL Better QOL Cardiac Arrest Moderate Obesity Myocardial Infarct Chrohn ’s Disease End-stage Haemodialysis Non-oxygen dependent COPD Back Pain Oxygen Dependent COPD Amyotrophic Lateral Sclerosis French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  8. Treatment aiming at modifying fertility Population A Population B Mean Age < 25 years Fecondity index > 4.0 Steep demography Mean age > 45 years Fecondity index < 1.0 Decreasing fertility Societal expectation Fertility preferable to contraception Contraception preferable to fertility The choice can be adapted but to context: time, location, fundamental needs for a given population It is not the mission of Ethics to judge over contexts French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  9. INNOVATION Responsibility for who undertakes research ? SCIENTIFIC PROGRESS ? MEDICAL PROGRESS ? INDIVIDUAL ? ECONOMICAL PROGRESS Responsibility for those who benefit from research SOCIETAL PROGRESS French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  10. New ethical developments and aspirations • Justice • Right to participate to clinical trials • Equity in sharing benefits and risks • Non exploitation of vulnerable subjects • Coupling research with improvement of medical care • Improvement of Research standards • Relevance of research vis-à-vis local needs • Account for local factors: culture, language • Account for global medical stakes, new or reemerging diseases, worldwide solidarity • Equity with regard to access to health information French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  11. Back-ups

  12. Human Research: the most codified activity • Universal Statements: • World Medical association: Helsinki Declaration (1964) • WHO: Manilla Declaration(1981) • CIOMS : Inuyama Declaration • UNESCO: Universal Declaration on Human Genome and Human Rights (1997) French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  13. Human Research: the most codified activity • A legislative, regulatory and ethical armamorium: • EU Council: Recommendations • Food & Drug Administration: Code of Federal Regulations • EU Commission: EU Directives and rulings • France: Public Health Bill (2004) • Deontology Code • Patient Rights Bill (2002) • Informatics and Liberties (laws and decrees) • Bioethics Law (2004) • CCNE: Opinions • Individuals Protection Committees (CPP) French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

  14. A very large Scope • Clinical Trials Conduct • Information and consent • Protection of the youngs and adults with incapacity • Trials in emergency situations • Safety statements and protections for specific products • Use of recombinent DNA • Use of human embryos • Genotyping • Patentability of human products • Gene therapy • Non commercialization of human genome • Data protection • Confidentiality French-Chinese Meeting - Ethics &- Innovation - Paris - February 23, 2007 - Y.PLETAN

More Related